Vitamin A Deficiency and Toxicity

Vitamin A metabolism and normal biochemical function

Mechanism 1: Impaired visual function in VAD

Mechanism 2: Corneal xerosis and epithelial differentiation defects in VAD

Mechanism 3: Immunologic dysfunction in VAD

Mechanism 4: Cellular differentiation and growth defects in VAD

Toxicity pathophysiology: Mechanism of hypervitaminosis A

Primary VAD causes (inadequate dietary intake)

• Dietary insufficiency in low-income countries: Predominant cause globally, typically in populations dependent on staple grains (rice, wheat) with limited access to animal products, fortified foods, or vitamin A–rich vegetables. Sub-Saharan Africa, South Asia, and Southeast Asia account for >95% of severe VAD cases.
• Malabsorption syndromes: Celiac disease, Crohn's disease, ulcerative colitis, cystic fibrosis, short bowel syndrome, and tropical sprue impair fat absorption, preventing retinol uptake from dietary sources. Cystic fibrosis patients particularly at risk due to pancreatic insufficiency and steatorrhea.
• Liver disease: Cirrhosis, hepatitis, and fatty liver disease impair hepatic storage and RBP synthesis, reducing plasma retinol delivery to tissues despite adequate dietary intake.
• Measles infection: Causes dramatic urinary and fecal losses of retinol and depletes hepatic stores; WHO recommends high-dose vitamin A supplementation in all children with measles to reduce morbidity and mortality.
• Protein-energy malnutrition: Deficiency of carrier proteins (RBP, transthyretin) prevents adequate vitamin A mobilization, even when hepatic stores are adequate; common in severe kwashiorkor.

Secondary VAD risk factors

• Zinc deficiency: Impairs synthesis of RBP and metalloproteins involved in retinol metabolism; zinc and vitamin A deficiencies frequently coexist.
• Renal disease: Nephrotic syndrome causes urinary RBP loss; chronic kidney disease reduces retinoic acid metabolism.
• Medications: Cholestyramine and mineral oil interfere with fat-soluble vitamin absorption; isotretinoin and acitretin (synthetic retinoids) increase vitamin A toxicity risk when combined with dietary sources.
• Premature infants: Immature hepatic and intestinal function, limited fat absorption capacity, and poor retinol stores at birth.

Vitamin A toxicity causes

• Chronic supplementation: Most common in developed countries, particularly from multivitamin overuse, motivated by beliefs in cancer and heart disease prevention (which have not been supported by randomized trials).
• Isotretinoin therapy: Used for severe acne, this synthetic retinoid is structurally related to vitamin A and carries high teratogenic and systemic toxicity risk; absolute contraindication in pregnancy (Category X).
• Hypervitaminosis A from foods: Polar bear liver, shark liver oil, and beef liver contain extremely high retinol concentrations; historically documented in Arctic explorers.
• Idiopathic hypercalcemia: Vitamin A toxicity can precipitate or worsen hypercalcemia through bone resorption.

Vitamin A Deficiency—Early and Progressive Features

Cardinal symptom—night blindness

Progressive ocular manifestations

• Conjunctival xerosis and Bitot spots: Early changes involve drying of the conjunctiva, appearing as foamy, triangular patches of keratinized epithelium on the temporal conjunctiva (Bitot spots), typically bilateral and pathognomonic for VAD. Patients may report eye grittiness or foreign body sensation. These changes precede corneal involvement and represent conjunctival metaplasia from mucinous to keratinized epithelium.
• Corneal xerosis and haze: Progressive corneal drying and clouding reflects loss of epithelial transparency due to keratinization and mucopolysaccharide depletion. Initially subtle haziness appears in the central cornea; advancement causes generalized opacification.
• Corneal scarring and neovascularization: Advanced VAD causes corneal melting (keratomalacia), ulceration, neovascularization, and irreversible scarring. Keratomalacia represents the transition from xerosis to structural corneal dissolution and is a medical emergency; blindness develops over days without urgent intervention.
• Photophobia: May accompany advanced corneal disease due to epithelial inflammation and ulceration.

Systemic signs and symptoms of VAD

• Growth retardation and developmental delay: Particularly pronounced in children; retinoic acid regulates bone development and growth hormone signaling. Children with severe VAD show stunted linear growth and delayed motor/cognitive development.
• Skin changes: Follicular hyperkeratosis (phrynoderma—"goose skin" appearance), dry, scaly skin reflecting epithelial metaplasia similar to ocular changes. Perifollicular edema and corkscrew hairs may be present.
• Respiratory and gastrointestinal manifestations: Increased susceptibility to respiratory infections (pneumonia, bronchitis) and diarrheal diseases. VAD impairs epithelial barrier integrity and immune function, creating a vicious cycle where infections worsen nutritional status.
• Anemia: Vitamin A deficiency may contribute to iron-refractory anemia through effects on erythropoietin signaling and iron metabolism; coexistence with iron deficiency common.

Physical exam findings in VAD

• Conjunctival xerosis and Bitot spots: Bilateral, triangular foamy patches on temporal conjunctiva, best visualized with magnification under slit lamp or direct visualization with good lighting. Pathognomonic finding.
• Corneal changes: Range from subtle haziness to obvious opacification, melting, or scarring depending on severity. Slit lamp examination required to fully characterize.
• Keratin plugging: May visualize follicular hyperkeratosis on skin examination.
• Signs of malnutrition: General appearance of wasting, edema (in protein deficiency), hair loss or brittle hair, nail changes.

Clinical variants and special populations

• Measles-associated VAD: Measles infection dramatically depletes vitamin A stores through increased urinary and fecal losses and hepatic consumption in immune response. Measles in VAD-endemic areas carries mortality risk of 5-10% (versus <0.1% in vitamin A–replete populations); WHO recommends immediate high-dose supplementation upon measles diagnosis.
• Premature infants: May present with poor growth, increased infection risk, and bronchopulmonary dysplasia exacerbation if vitamin A not supplemented.
• VAD in malabsorptive disease: May be masked by other nutritional deficiencies (zinc, iron, protein) with overlapping clinical features.

Vitamin A Toxicity—Acute and Chronic Presentations

Acute toxicity (from single massive dose >200,000 IU/kg)

• Intoxication-like syndrome: Develops within hours; symptoms include severe headache (often frontal, mimicking increased intracranial pressure), dizziness, nausea, vomiting, and desquamation of skin. Patients may appear toxic/ill.
• Neurologic signs: Pseudotumor cerebri signs (papilledema, visual blurring, headache) can develop and may be mistaken for intracranial pathology.
• Cutaneous manifestations: Acute erythema and peeling of skin, particularly on face and extremities.

Chronic toxicity (from prolonged elevation >15,000 IU/day in adults, lower thresholds in children)

• Skeletal manifestations: Bone pain, arthralgias (particularly affecting ankles, knees, shoulders), and exostoses. Excess vitamin A stimulates osteoclasts via RANKL upregulation and suppresses osteoblast differentiation, causing net bone loss. Skeletal radiographs may show cortical thickening or hyperostosis, particularly of long bones and spine.
• Hepatic manifestations: Hepatomegaly, elevated transaminases, cirrhosis with prolonged excess. Portal fibrosis and cirrhosis develop insidiously. Histology shows hepatocyte damage and activation of stellate cells with collagen deposition.
• Mucocutaneous findings: Dry, scaly skin; alopecia; brittle nails; and cheilitis (cracked lips). Paradoxically, the skin appears similar to VAD because of the metaplastic effects of excess retinoic acid.
• Neurologic symptoms: Headache (from pseudotumor cerebri), dizziness, irritability, and fatigue.
• Teratogenic effects (in pregnancy): Vitamin A toxicity in pregnancy (doses >10,000 IU/day, or 3,000 μg/day) is associated with craniofacial defects (cleft palate), cardiac malformations, CNS malformations, and thymic hypoplasia. This is a critical counseling point in women of childbearing age.

Physical exam findings in toxicity

• Alopecia and dry skin: Diffuse hair loss and xerosis.
• Hepatomegaly: Firm, enlarged liver with possible evidence of cirrhosis (ascites, spider angiomas).
• Neurologic exam: Possible papilledema (pseudotumor cerebri), ataxia, or hyperreflexia.

Clinical history and risk assessment

Serum retinol measurement (gold standard for VAD diagnosis)

• Serum retinol <20 μg/dL (0.7 μmol/L): Indicates VAD; values <10 μg/dL represent severe deficiency.
• Serum retinol 20-30 μg/dL: Marginal deficiency with depleted hepatic stores despite minimally abnormal serum level (reflects adaptive response with RBP down-regulation).
• Interpretation caveat: Serum retinol is a poor indicator of body stores because hepatic storage is tightly regulated; levels remain normal until hepatic reserves are substantially depleted. Serum retinol <20 μg/dL indicates clinical deficiency, but normal levels do NOT exclude VAD in the setting of acute malabsorption, liver disease, or protein deficiency (when RBP synthesis is impaired despite adequate retinoid stores).

Immediate priorities

• Xerophthalmia with corneal involvement is a sight-threatening emergency: corneal xerosis, ulceration, or keratomalacia requires same-day high-dose vitamin A plus urgent ophthalmology consultation. Do not wait for a confirmatory serum retinol — treat on clinical suspicion.
• Adjunctive eye care: topical broad-spectrum antibiotic ointment to prevent secondary bacterial keratitis, protective shielding, and avoidance of pressure on a thinned or perforating globe.

First-line therapy — oral retinyl palmitate/retinyl acetate

• Xerophthalmia regimen (WHO): high-dose oral vitamin A on day 1, day 2, and again at approximately 2 weeks — 200,000 IU for children ≥12 months, 100,000 IU for infants 6–11 months, 50,000 IU for infants <6 months.
• Measles regimen (WHO, AAP Red Book, CDC): two doses on consecutive days at the same age-based dosing. A third dose 2–4 weeks later is added only when there are ocular signs of deficiency or severe malnutrition. AAP/CDC endorse vitamin A for children with measles in the United States as well — regardless of baseline nutritional status, particularly hospitalized children and those 6 months to 2 years — given under physician supervision.
• Why repeat dosing: a single dose saturates hepatic stellate-cell stores only transiently; subsequent doses replenish the reservoir and cover ongoing urinary/fecal retinol losses during acute infection.

Escalation and second-line measures

• Water-miscible intramuscular retinol (approximately 100,000 IU) when severe vomiting or steatorrhea prevents oral absorption (cystic fibrosis, cholestasis, short bowel, post-bariatric anatomy). Only water-miscible preparations are suitable for IM use; oil-based preparations are poorly absorbed from muscle and should not be used. Pancreatic enzyme replacement and treatment of the underlying malabsorption are definitive.
• Correct cofactor deficiencies: zinc repletion restores retinol-binding protein synthesis, and protein-energy repletion restores RBP/transthyretin carriage — without these, serum retinol will not normalize despite dosing.
• Treat the driving illness: measles, diarrheal disease, and pneumonia both deplete and are worsened by deficiency.

Prevention and contraindications

• Periodic supplementation and food fortification in endemic regions (WHO), and routine intake per NASEM Dietary Reference Intakes elsewhere.
• High-dose vitamin A is contraindicated in pregnancy — preformed retinol above the NASEM tolerable upper intake level is teratogenic; ACOG advises against megadose supplements, and beta-carotene is the safer source. Isotretinoin requires the FDA iPLEDGE REMS with two contraception methods and serial pregnancy testing.
• Treatment of toxicity is discontinuation, not chelation: stop all retinoid sources, monitor transaminases, manage hypercalcemia with isotonic saline volume expansion, and treat retinoid-induced intracranial hypertension with drug withdrawal and a carbonic anhydrase inhibitor such as acetazolamide.

Complications of deficiency

• Irreversible corneal blindness (emergency): keratomalacia progresses from stromal melting to perforation within days; the signal is a soft, hazy, or frankly liquefying cornea, sometimes with iris prolapse. Once scarring occurs, retinol repletion restores nothing — only keratoplasty can.
• Secondary bacterial keratitis and endophthalmitis (emergency): loss of the keratinized, mucin-poor epithelial barrier permits invasion; hypopyon or a purulent infiltrate signals it.
• Death from measles, pneumonia, and diarrheal illness: loss of retinoic acid–driven Treg differentiation, secretory IgA production, and epithelial tight-junction integrity yields disproportionate infectious mortality — the reason WHO ties supplementation to measles case management.
• Growth stunting and delayed development in children, reflecting impaired RAR/RXR-dependent bone modeling and growth hormone signaling.
• Iron-refractory anemia: retinol deficiency impairs iron mobilization and erythropoiesis; hemoglobin fails to rise on iron alone.

Complications of treatment

• Acute hypervitaminosis A from high-dose repletion: transient vomiting, headache, and irritability; in infants a bulging fontanelle is the classic sign. Usually self-limited, but papilledema with visual field loss is an emergency.
• Teratogenicity (emergency to prevent, not to treat): preformed retinol or isotretinoin during organogenesis produces craniofacial, cardiac, CNS, and thymic (branchial arch–derived) defects. The signal is a positive pregnancy test in a patient on a retinoid — stop immediately.

Complications of chronic toxicity

• Retinoid-induced intracranial hypertension (pseudotumor cerebri) (emergency for vision): excess retinoid impairs CSF absorption; headache with papilledema, unremarkable parenchymal neuroimaging, and elevated opening pressure on LP with normal CSF composition. Venous imaging (MR or CT venography) is required to exclude cerebral venous sinus thrombosis before attributing papilledema to the retinoid.
• Hepatic stellate-cell activation → fibrosis, cirrhosis, portal hypertension: hepatomegaly with transaminase elevation, later ascites and varices; non-cirrhotic portal hypertension is characteristic.
• Hypercalcemia and fragility fracture: RANKL-driven osteoclast activation with osteoblast suppression; suspect with bone pain, cortical hyperostosis on radiographs, or unexplained hypercalcemia with suppressed PTH.

• **Night blindness is the first symptom; conjunctival xerosis is the earliest visible sign, with Bitot spots the classic, near-pathognomonic finding**: foamy, triangular, keratinized patches on the temporal bulbar conjunctiva. Nyctalopia is fully reversible; corneal scarring is not.
• Single best next step in a child with measles: give high-dose oral vitamin A immediately (WHO, AAP Red Book/CDC) — two doses on consecutive days. A third dose 2–4 weeks later is added only for ocular signs of deficiency or severe malnutrition. AAP/CDC support vitamin A for US children with measles regardless of nutritional status, under physician supervision. Do not delay treatment for a serum retinol level.
• Don't conflate the regimens: the three-dose schedule (day 1, day 2, ~2 weeks) is the WHO xerophthalmia treatment regimen, not the routine measles regimen.
• The one association examiners love: fat malabsorption. Cystic fibrosis, cholestasis, celiac disease, and post-bariatric anatomy cause combined A/D/E/K deficiency — look for night blindness alongside easy bruising (K) or ataxia and hemolysis (E).
• Teratogen alert: isotretinoin and megadose preformed retinol cause craniofacial, cardiac, CNS, and thymic hypoplasia defects. iPLEDGE (FDA) requires two contraceptive methods and serial pregnancy tests. Beta-carotene is not teratogenic — its conversion to retinol is under feedback control.
• Classic distractor — carotenemia: yellow-orange skin with white sclerae from carrot/squash intake. Benign, and not hypervitaminosis A; scleral icterus points to hyperbilirubinemia instead.
• Second classic distractor — headache with papilledema in a teenager on acne therapy: think retinoid-induced intracranial hypertension, not a mass lesion. Parenchymal imaging is unremarkable and LP shows elevated opening pressure — but obtain venous imaging (MRV/CTV) to exclude cerebral venous sinus thrombosis first. Combining isotretinoin with a tetracycline compounds the risk.
• Chronic toxicity buzzwords: alopecia, cheilitis, dry scaly skin, bone/joint pain with cortical hyperostosis, hepatomegaly, and hypercalcemia — remember the polar bear liver vignette.
• All-trans retinoic acid treats APL (t(15;17)), and differentiation syndrome (fever, dyspnea, pulmonary infiltrates, weight gain) is its feared complication — treated with dexamethasone. Don't confuse this therapeutic retinoid with nutritional toxicity.